{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:58:12Z","timestamp":1773709092510,"version":"3.50.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100011608","name":"Canadian Paediatric Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In 2010, the World Health Organization (WHO) increased the recommended doses of first-line tuberculosis (TB) drugs for children. In this systematic review, we aimed to determine the proportion of children who developed adverse events (AEs) on first-line TB treatment and determine whether a change in toxicity was observed with WHO 2010 dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched MEDLINE, Embase, Scopus, Cochrane Central Register of Controlled Trials, WHO Global Index Medicus, and ClinicalTrials.gov for studies that reported AEs for children and adolescents aged \u226419 years with TB disease receiving first-line medications. A meta-analysis of proportions was performed to generate pooled proportions of AEs. The protocol was registered with the International Prospective Register of Systematic Reviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of forty studies comprising 5021 participants, 682 (13.6%) participants experienced 712 AEs; 60 (1.2%) participants experienced a change in therapy due to AEs. The proportion of children with any AE was significantly higher with WHO 2010 dosing (26%; 95% confidence interval [CI], 18%\u201334%) compared with pre-WHO 2010 dosing (8%, 95% CI, 4%\u201315%), as was the proportion of children who developed severe AEs. There was no significant difference in hepatotoxicity before and after 2010 dosing recommendations; however, significant increases in hepatotoxicity were seen in several subgroups with 2010 dosing. There was substantial heterogeneity between studies; none were at high risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher-dose regimens in children were associated with increased AEs, raising caution for further dose increases and necessitating additional study of treatment tolerability. These findings are limited by publication bias in observational trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf152","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:43:28Z","timestamp":1742719408000},"page":"501-512","source":"Crossref","is-referenced-by-count":1,"title":["Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-5301","authenticated-orcid":false,"given":"Michael","family":"Prodanuk","sequence":"first","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Infectious Diseases, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-5879","authenticated-orcid":false,"given":"Sarah L","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Infectious Diseases, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-6877","authenticated-orcid":false,"given":"Pierre-Philippe","family":"Pich\u00e9-Renaud","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Infectious Diseases, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7823-1912","authenticated-orcid":false,"given":"Daniel S","family":"Farrar","sequence":"additional","affiliation":[{"name":"Centre for Global Child Health, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-0515","authenticated-orcid":false,"given":"Jessie","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Hospital Library, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0155-7377","authenticated-orcid":false,"given":"Fiona","family":"Kritzinger","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Respirology, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Waters","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Infectious Diseases, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9725-9217","authenticated-orcid":false,"given":"Ray","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Kitai","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Infectious Diseases, The Hospital for Sick Children , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"2026031619530257500_ciaf152-B1","volume-title":"Rapid advice: treatment of tuberculosis in children","author":"World Health Organization","year":"2010"},{"key":"2026031619530257500_ciaf152-B2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"2026031619530257500_ciaf152-B3","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.3390\/ijerph18147574","article-title":"Adverse drug reactions among children with tuberculosis in Tashkent, Uzbekistan, 2019","volume":"18","author":"Abdusalomova","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026031619530257500_ciaf152-B4","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ijtb.2023.07.004","article-title":"Adverse drug reactions in children and adolescents on daily antitubercular regimen: an observational longitudinal study","volume":"70","author":"Agarwal","year":"2023","journal-title":"Indian J Tuberc"},{"key":"2026031619530257500_ciaf152-B5","first-page":"431","article-title":"Pediatric tuberculosis in Turkey: a review of 8-years period in a tertiary care hospital","volume":"57","author":"Bayhan","year":"2015","journal-title":"Turk J Pediatr"},{"key":"2026031619530257500_ciaf152-B6","doi-asserted-by":"crossref","first-page":"e97267","DOI":"10.1371\/journal.pone.0097267","article-title":"Childhood tuberculosis in northern Viet Nam: a review of 103 cases","volume":"9","author":"Blount","year":"2014","journal-title":"PLoS One"},{"key":"2026031619530257500_ciaf152-B7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ped4.12266","article-title":"Clinical characteristics and post-discharge follow-up analyses of 10 infants with congenital tuberculosis: a retrospective observational study","volume":"5","author":"Du","year":"2021","journal-title":"Pediatr Investig"},{"key":"2026031619530257500_ciaf152-B8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/INF.0000000000002192","article-title":"Antituberculosis drug-induced liver injury in children","volume":"38","author":"Gafar","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2026031619530257500_ciaf152-B9","first-page":"9","article-title":"N-acetyltransferase2 genotype and its association with hepatitis among Filipino children treated with first line anti-tuberculosis drugs","volume":"45","author":"Gregorio","year":"2011","journal-title":"Acta Med Philipp"},{"key":"2026031619530257500_ciaf152-B10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/TACG.S303668","article-title":"NAT2 gene rs1041983 is associated with anti-tuberculosis drug induced hepatotoxicity among pediatric tuberculosis in Bandung, Indonesia","volume":"14","author":"Headriawan","year":"2021","journal-title":"Appl Clin Genet"},{"key":"2026031619530257500_ciaf152-B11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12098-018-2812-z","article-title":"Revised antituberculosis drug doses and hepatotoxicity in HIV negative children","volume":"86","author":"Indumathi","year":"2019","journal-title":"Indian J Pediatr"},{"key":"2026031619530257500_ciaf152-B12","first-page":"927","article-title":"Category based treatment of tuberculosis in children","volume":"41","author":"Kabra","year":"2004","journal-title":"Indian J Pediatr"},{"key":"2026031619530257500_ciaf152-B13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/09273948.2017.1296579","article-title":"Clinical course and outcomes of pediatric tubercular uveitis in north India","volume":"26","author":"Kaur","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"2026031619530257500_ciaf152-B14","doi-asserted-by":"crossref","first-page":"fmaa125","DOI":"10.1093\/tropej\/fmaa125","article-title":"Comparing treatment outcomes between confirmed and non-confirmed childhood TB cases: study from a major tertiary center in Thailand","volume":"67","author":"Khantee","year":"2021","journal-title":"J Trop Pediatr"},{"key":"2026031619530257500_ciaf152-B15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/00006454-199011000-00004","article-title":"A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis","volume":"9","author":"Kumar","year":"1990","journal-title":"Pediatr Infect Dis J"},{"key":"2026031619530257500_ciaf152-B16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/026886900417397","article-title":"Brain stem tuberculosis in children","volume":"14","author":"Kumar","year":"2000","journal-title":"Br J Neurosurg"},{"key":"2026031619530257500_ciaf152-B17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13312-022-2644-9","article-title":"Ocular toxicity of ethambutol during both intensive and continuation phases of anti-tubercular therapy in children","volume":"59","author":"Mane","year":"2022","journal-title":"Indian Pediatr"},{"key":"2026031619530257500_ciaf152-B18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1665-2681(19)31492-9","article-title":"Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy","volume":"11","author":"Mansukhani","year":"2012","journal-title":"Ann Hepatol"},{"key":"2026031619530257500_ciaf152-B19","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1007\/s12098-022-04317-7","article-title":"A prospective observational study of hepatic dysfunction in children on antitubercular drugs","volume":"89","author":"Mehra","year":"2022","journal-title":"Indian J Pediatr"},{"key":"2026031619530257500_ciaf152-B20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1067\/mcp.2002.126175","article-title":"Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients","volume":"72","author":"Ohkawa","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"2026031619530257500_ciaf152-B21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/archdischild-2020-321426","article-title":"Pharmacokinetics and safety\/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis","volume":"107","author":"Ruslami","year":"2022","journal-title":"Arch Dis Child"},{"key":"2026031619530257500_ciaf152-B22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000534786","article-title":"Clinical features, diagnosis, and treatment of congenital and neonatal tuberculosis: a retrospective study","volume":"121","author":"Zhou","year":"2024","journal-title":"Neonatology"},{"key":"2026031619530257500_ciaf152-B23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/tropej\/fmv042","article-title":"Is hyperuricemia overlooked when treating pediatric tuberculosis patients with pyrazinamide?","volume":"61","author":"\u015ei\u015fmanlar","year":"2015","journal-title":"J Trop Pediatr"},{"key":"2026031619530257500_ciaf152-B24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4314\/ejhs.v27i2.3","article-title":"Hepatotoxicity due to antituberculosis therapy among paediatric patients seen at the University of Ilorin Teaching Hospital, North Central Nigeria","volume":"27","author":"Aishatu","year":"2017","journal-title":"Ethiop J Health Sci"},{"key":"2026031619530257500_ciaf152-B25","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/jac\/dkab336","article-title":"Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial","volume":"76","author":"Garcia-Prats","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026031619530257500_ciaf152-B26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5588\/ijtld.17.0535","article-title":"Treatment outcomes and tolerability of the revised WHO anti-tuberculosis drug dosages for children","volume":"22","author":"Nansumba","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026031619530257500_ciaf152-B27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ppul.23221","article-title":"Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children","volume":"51","author":"Van Rie","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"2026031619530257500_ciaf152-B28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00006454-200202000-00002","article-title":"Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy","volume":"21","author":"Al-Dossary","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"2026031619530257500_ciaf152-B29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/archdischild-2021-322092","article-title":"Epidemiology, clinical features and outcomes of incident tuberculosis in children in Canada in 2013\u20132016: results of a national surveillance study","volume":"106","author":"Morris","year":"2021","journal-title":"Arch Dis Child"},{"key":"2026031619530257500_ciaf152-B30","first-page":"430","article-title":"Peripheral tuberculous lymphadenitis in pediatrics: 16 years of experience in a tertiary care pediatric hospital of Buenos Aires, Argentina","volume":"116","author":"Neyro","year":"2018","journal-title":"Arch Argent Pediatr"},{"key":"2026031619530257500_ciaf152-B31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2016.08.009","article-title":"Paradoxical reaction in immunocompetent children with tuberculosis","volume":"51","author":"Carazo Gallego","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2026031619530257500_ciaf152-B32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1468-1293.2008.00559.x","article-title":"Presentation, diagnosis and management of tuberculosis in HIV-infected children in the United Kingdom","volume":"9","author":"Cohen","year":"2008","journal-title":"HIV Med"},{"key":"2026031619530257500_ciaf152-B33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/(SICI)1099-0496(199901)27:1<37::AID-PPUL8>3.0.CO;2-G","article-title":"Hepatic enzyme abnormalities in children on triple therapy for tuberculosis","volume":"27","author":"Corrigan","year":"1999","journal-title":"Pediatr Pulmonol"},{"key":"2026031619530257500_ciaf152-B34","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3109\/00365548.2010.508461","article-title":"Tuberculosis among children in Oslo, Norway, from 1998 to 2009","volume":"42","author":"Krogh","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"2026031619530257500_ciaf152-B35","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/INF.0b013e3182846c4e","article-title":"Paradoxical reaction during tuberculosis treatment in immunocompetent children","volume":"32","author":"Olive","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2026031619530257500_ciaf152-B36","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00006454-199708000-00006","article-title":"Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children","volume":"16","author":"S\u00e1nchez-Albisua","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"2026031619530257500_ciaf152-B37","doi-asserted-by":"crossref","first-page":"e0213718","DOI":"10.1371\/journal.pone.0213718","article-title":"High-dose rifampicin in tuberculosis: experiences from a Dutch tuberculosis centre","volume":"14","author":"Seijger","year":"2019","journal-title":"PLoS One"},{"key":"2026031619530257500_ciaf152-B38","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00006454-199211120-00009","article-title":"Intensive short course chemotherapy for treatment of Greek children with tuberculosis","volume":"11","author":"Tsakalidis","year":"1992","journal-title":"Pediatr Infect Dis J"},{"key":"2026031619530257500_ciaf152-B39","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.5588\/ijtld.16.0370","article-title":"Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period","volume":"20","author":"Bright-Thomas","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026031619530257500_ciaf152-B40","doi-asserted-by":"crossref","first-page":"EVIDoa2300054","DOI":"10.1056\/EVIDoa2300054","article-title":"Four-month high-dose rifampicin regimens for pulmonary tuberculosis","volume":"2","author":"Jindani","year":"2023","journal-title":"NEJM Evid"},{"key":"2026031619530257500_ciaf152-B41","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/cid\/ciac208","article-title":"Randomized clinical trial of high-dose rifampicin with or without levofloxacin versus standard of care for pediatric tuberculous meningitis: the TBM-KIDS trial","volume":"75","author":"Paradkar","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031619530257500_ciaf152-B42","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2104535","article-title":"Shorter treatment for nonsevere tuberculosis in African and Indian children","volume":"386","author":"Turkova","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031619530257500_ciaf152-B43","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031619530257500_ciaf152-B44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S2213-2600(24)00076-6","article-title":"High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial","volume":"12","author":"Ruslami","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026031619530257500_ciaf152-B45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijid.2023.05.002","article-title":"High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin","volume":"133","author":"Souleymane","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2026031619530257500_ciaf152-B46","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/cid\/ciab725","article-title":"Pharmacokinetics of first-line drugs in children with tuberculosis, using World Health Organization\u2013recommended weight band doses and formulations","volume":"74","author":"Chabala","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031619530257500_ciaf152-B47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cid\/ciab908","article-title":"Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: a prospective population pharmacokinetic study","volume":"75","author":"Denti","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031619530257500_ciaf152-B48","doi-asserted-by":"crossref","first-page":"23992026211070406","DOI":"10.1177\/23992026211070406","article-title":"Tackling the global impact of substandard and falsified and unregistered\/unlicensed anti-tuberculosis medicines","volume":"6","author":"Akpobolokemi","year":"2022","journal-title":"J Med Access"},{"key":"2026031619530257500_ciaf152-B49","volume-title":"WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents","author":"World Health Organization","year":"2022"},{"key":"2026031619530257500_ciaf152-B50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.5588\/ijtld.17.0596","article-title":"Interventions to improve adherence to tuberculosis treatment: systematic review and meta-analysis","volume":"22","author":"M\u00fcller","year":"2018","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf152\/62574878\/ciaf152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/501\/62574878\/ciaf152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/501\/62574878\/ciaf152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:53:19Z","timestamp":1773705199000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/3\/501\/8092576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,24]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf152","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,15]]},"published":{"date-parts":[[2025,3,24]]}}}